This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept
Donate

DMPA-SC Self-Injection Feasibility and Acceptability Brief

Subcutaneous DMPA (DMPA-SC, Sayana® Press) is a new, easy-to-use injectable contraceptive that is ideally suited for remote access and even self-injection. This brief provides an overview of PATH’s research studies assessing the feasibility and acceptability of self-injection in Uganda and Senegal. For more information, please visit www.path.org/dmpa-sc or email FPoptions@path.org.

Corporate author(s): PATH

Publication date: January 2018

Available materials

  1. English

    1. Self-Injection Feasibility and Acceptability brief 669.1 KB PDF

      Hard copies are not available.

  2. French

    1. Self-Injection Feasibility and Acceptability brief [French] 674.5 KB PDF

      Hard copies are not available.